litlas
ログインアカウント作成

Ingrid A. Mayer

2000–2025 年に発表

111
論文数
30,753
被引用数
73
h 指数
108
i10 指数

被引用数

Ingrid A. Mayer の年別被引用数1981 年: 被引用 1 件1984 年: 被引用 1 件1993 年: 被引用 1 件1996 年: 被引用 1 件1999 年: 被引用 2 件2001 年: 被引用 8 件2002 年: 被引用 18 件2003 年: 被引用 19 件2004 年: 被引用 9 件2005 年: 被引用 7 件2006 年: 被引用 10 件2007 年: 被引用 6 件2008 年: 被引用 23 件2009 年: 被引用 38 件2010 年: 被引用 60 件2011 年: 被引用 97 件2012 年: 被引用 88 件2013 年: 被引用 86 件2014 年: 被引用 108 件2015 年: 被引用 132 件2016 年: 被引用 148 件2017 年: 被引用 208 件2018 年: 被引用 281 件2019 年: 被引用 1,327 件2020 年: 被引用 1,725 件2021 年: 被引用 1,865 件2022 年: 被引用 1,562 件2023 年: 被引用 1,160 件2024 年: 被引用 1,628 件2025 年: 被引用 755 件2026 年: 被引用 30 件1982〜1983 年は被引用が無いため表示していません1985〜1992 年は被引用が無いため表示していません1994〜1995 年は被引用が無いため表示していません1997〜1998 年は被引用が無いため表示していません2000 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,794 件、この内訳の 24.9%中国: 引用元論文 2,308 件、この内訳の 15.1%イタリア: 引用元論文 872 件、この内訳の 5.7%イギリス: 引用元論文 715 件、この内訳の 4.7%ドイツ: 引用元論文 662 件、この内訳の 4.4%フランス: 引用元論文 544 件、この内訳の 3.6%カナダ: 引用元論文 517 件、この内訳の 3.4%スペイン: 引用元論文 516 件、この内訳の 3.4%韓国: 引用元論文 371 件、この内訳の 2.4%日本: 引用元論文 364 件、この内訳の 2.4%オーストラリア: 引用元論文 340 件、この内訳の 2.2%スイス: 引用元論文 324 件、この内訳の 2.1%
0%24.9%その他 25.7%

機関

分野

  • Medicine51.2%
  • Biochemistry, Genetics and Molecular Biology39.7%
  • Immunology and Microbiology2.2%
  • Computer Science1.9%
  • Engineering1.3%
  • Chemistry0.8%
  • その他2.9%

トピック

  • Breast Cancer Treatment Studies6.8%
  • HER2/EGFR in Cancer Research5.9%
  • Advanced Breast Cancer Therapies5.1%
  • Cancer Genomics and Diagnostics3.3%
  • Cancer Cells and Metastasis2.4%
  • PI3K/AKT/mTOR signaling in cancer2.4%
  • その他74.1%

共著者

全論文

検索で開く
  1. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    著者: Fabrice André, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, Hope S. Rugo, Hiroji Iwata, PierFranco Conte, Ingrid A. Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masato Takahashi, Zsuzsanna Pápai, Anne-Sophie Longin, David Mills, Celine Wilke, Samit Hirawat, Dejan Juric - New England Journal of Medicine 2019 被引用: 2,572

  2. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

    著者: Giampaolo Bianchini, Justin M. Balko, Ingrid A. Mayer, Melinda E. Sanders, Luca Gianni - Nature Reviews Clinical Oncology 2016 被引用: 3,072

  3. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    著者: Joseph A. Sparano, Robert J. Gray, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Peter M. Ravdin, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, Jeffrey L. Berenberg, Jeffrey S. Abrams, George W. Sledge - New England Journal of Medicine 2018 被引用: 2,369

  4. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

    著者: Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan, Robert Iannone, Sarah A. Washkowitz, Robert M. Sharkey, William A. Wegener, Kevin Kalinsky - New England Journal of Medicine 2019 被引用: 850

  5. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

    著者: William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice A. Lyons, P. Kelly Marcom, Jennifer M. Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth O’Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica Young, Jennifer L. Burns, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2020 被引用: 1,618

  6. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

    著者: Fabrice André, Eva Ciruelos, Dejan Juric, Sibylle Loibl, Mario Campone, Ingrid A. Mayer, Gábor Rubovszky, Toshinari Yamashita, Bella Kaufman, Yen‐Shen Lu, Kenichi Inoue, Zsuzsanna Pápai, Masato Takahashi, Farhat Ghaznawi, David Mills, Mathilde Kaper, Michelle C. Miller, PierFranco Conte, Hiroji Iwata, Hope S. Rugo - Annals of Oncology 2020 被引用: 599

  7. Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer

    著者: Pamela J. Goodwin, Bingshu E. Chen, Karen A. Gelmon, Timothy J. Whelan, Marguerite Ennis, Julie Lemieux, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Hobday, Judith M. Bliss, Priya Rastogi, Manuela Rabaglio, Som D. Mukherjee, John R. Mackey, Vandana G. Abramson, Conrad D. Oja, Robert Wesolowski, Alastair M. Thompson, Daniel Rea, Paul M. Stos, Lois E. Shepherd, Vuk Stambolic, Wendy R. Parulekar - JAMA 2022 被引用: 223

  8. HER kinase inhibition in patients with HER2- and HER3-mutant cancers

    著者: David M. Hyman, Sarina A. Piha‐Paul, Helen Won, Jordi Rodón, Cristina Saura, Geoffrey I. Shapiro, Dejan Juric, David I. Quinn, Víctor Moreno, Bernard Doger, Ingrid A. Mayer, Valentina Boni, Emiliano Calvo, Sherene Loi, A. Craig Lockhart, Joseph P. Erinjeri, Maurizio Scaltriti, Gary A. Ulaner, Juber Patel, Jiabin Tang, Hannah Beer, S. Duygu Selçuklu, Aphrothiti J. Hanrahan, Nancy Bouvier, Myra Melcer, Rajmohan Murali, Alison M. Schram, Lillian M. Smyth, Komal Jhaveri, Bob T. Li, Alexander Drilon, James J. Harding, Gopa Iyer, Barry S. Taylor, Michael F. Berger, Richard E. Cutler, Feng Xu, Anna Butturini, Lisa D. Eli, Grace Mann, Cynthia Farrell, Alshad S. Lalani, Richard Bryce, Carlos L. Arteaga, Funda Meric‐Bernstam, José Baselga, David B. Solit - Nature 2018 被引用: 788

  9. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

    著者: Otto Metzger, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia Dell’Orto, Leila Russo, Tari A. King, Kornélia Polyák, Franziska Michor, Eric P. Winer, Ian E. Krop - Cancer Discovery 2021 被引用: 240

  10. The PI3K/AKT Pathway as a Target for Cancer Treatment

    著者: Ingrid A. Mayer, Carlos L. Arteaga - Annual Review of Medicine 2015 被引用: 840

  11. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

    著者: Michael Gnant, Amylou C. Dueck, Sophie Frantal, Miguel Martín, H.J. Burstein, Richard Greil, Peter Fox, Antonio C. Wolff, Arlene Chan, Eric P. Winer, Georg Pfeiler, Kathy D. Miller, Marco Colleoni, Jennifer M. Suga, Gabor Rubovsky, Judith M. Bliss, Ingrid A. Mayer, Christian F. Singer, Zbigniew Nowecki, Olwen Hahn, Jacqui Thomson, Norman Wolmark, Kepa Amillano, Hope S. Rugo, Guenther G. Steger, Blanca Hernando Fernández de Aranguiz, Tufia C. Haddad, Antonia Perelló, Meritxell Bellet, Hannes Fohler, Otto Metzger, Anita Jallitsch-Halper, Kadine Solomon, Céline Schurmans, K. P. Theall, Dongrui R. Lu, Kathleen Tenner, Christian Fesl, Angela DeMichele, Erica L. Mayer, on behalf of the PALLAS groups and investigators - Journal of Clinical Oncology 2021 被引用: 231

  12. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

    著者: Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond, Rebecca Moroose, Steven J. Isakoff, Alexander Starodub, Nikita Shah, Joyce O’Shaughnessy, Kevin Kalinsky, Michael J. Guarino, Vandana G. Abramson, Dejan Juric, Sara M. Tolaney, Jordan Berlin, Wells A. Messersmith, Allyson J. Ocean, William A. Wegener, Pius Maliakal, Robert M. Sharkey, Serengulam V. Govindan, David M. Goldenberg, Linda T. Vahdat - Journal of Clinical Oncology 2017 被引用: 409

  13. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

    著者: Luigi Formisano, Yao Lu, Alberto Servetto, Ariella B. Hanker, Valerie M. Jansen, Joshua A. Bauer, Dhivya R. Sudhan, Ángel Guerrero‐Zotano, Sarah Croessmann, Yan Guo, Paula I. González-Ericsson, Kyung‐min Lee, Mellissa J. Nixon, Luis J. Schwarz, Melinda E. Sanders, Teresa C. Dugger, Marcelo Cruz, Amir Behdad, Massimo Cristofanilli, Aditya Bardia, Joyce O’Shaughnessy, Rebecca J. Nagy, Richard B. Lanman, Nadia Solovieff, Wei He, Michelle C. Miller, Fei Su, Yu Shyr, Ingrid A. Mayer, Justin M. Balko, Carlos L. Arteaga - Nature Communications 2019 被引用: 419

  14. Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

    著者: Allyson J. Ocean, Alexander Starodub, Aditya Bardia, Linda T. Vahdat, Steven J. Isakoff, Michael J. Guarino, Wells A. Messersmith, Vincent J. Picozzi, Ingrid A. Mayer, William A. Wegener, Pius Maliakal, Serengulam V. Govindan, Robert M. Sharkey, David M. Goldenberg - Cancer 2017 被引用: 236

  15. Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer

    著者: Sara Nunnery, Ingrid A. Mayer - Drugs 2020 被引用: 202

  16. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

    著者: Joseph A. Sparano, Robert J. Gray, Peter M. Ravdin, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, Jeffrey L. Berenberg, Jeffrey S. Abrams, George W. Sledge - New England Journal of Medicine 2019 被引用: 555

  17. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    著者: Joseph A. Sparano, Robert J. Gray, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Edith A. Perez, John A. Olson, JoAnne Zujewski, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Peter M. Ravdin, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, James N. Atkins, Jeffrey L. Berenberg, George W. Sledge - New England Journal of Medicine 2015 被引用: 1,439

  18. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gϋnter von Minckwitz, Stephen Chia, Janine Mansi, Carlos H. Barrios, Michael Gnant, Z. Tomasevic, Neelima Denduluri, Robert Šeparović, Erhan Gökmen, Anna Bashford, Manuel Ruíz Borrego, Sung‐Bae Kim, Erik Jakobsen, A. Ciceniene, Kenichi Inoue, Friedrich Overkamp, Joan B. Heijns, Anne Armstrong, John S. Link, Anil A. Joy, Richard Bryce, Alvin Wong, Susan Moran, Bin Yao, Feng Xu, Alan Auerbach, Marc Buyse, Arlene Chan, Vernon Harvey, Rudolf Tomek, Nicholas J. Robert, Ira Gore, John W. Smith, Norikazu Masuda, S. Di Sean Kendall, William Graydon Harker, Katarína Petráková, Ángel Guerrero‐Zotano, Amparo Ruiz Simón, Zora Neskovic Konstantinovic, Nicholas Iannotti, Pierfrancesco Tassone, Gladys Rodriguez, Noelia Jáñez Martínez, Carmen Crespo Massieu, Snezana Smickoska, Işıl Somali, Uğur Yılmaz, Mirta Garcia Alonso, Adolfo Rosales, Soeren Cold, Ann Knoop, Debra A. Patt, Beth A. Hellerstedt, Serafin Morales Murillo, Ingrid A. Mayer, Julie A. Means‐Powell, Rina Hui, Francis M. Senecal, Richard Hendry De Boer, Zhenzhou Shen, A.A. Luczak, Joanna W.Y. Chui, Janice Tsang, István Láng, Yoshiaki Rai, Yasuo Hozumi, Albert J. ten Tije, Manish Bhandari, Cynthia R. Osborne, Shoichiro Ohtani, Kenji Higaki, Kenichi Watanabe, Kazunori TAGUCHI, Masato Takahashi, Sladjana Filipovic, Vincent Hansen, Vijayarama Phooshkooru Rao, Manish Gupta, Petar Petrov, Bruno Coudert, Željko Vojnović, Zsofia Polya, Toshiko Miyaki, Naohito Yamamoto, Stephen Brincat, Krzysztof Leśniewski-Kmak, Ewa Chmielowska, Ruemu Birhiray, Marc L. Citron, Steven W. Papish, William L. Berry, Sven Tyge Langkjer, José Á. García-Sáenz ほか 526 名 - The Lancet Oncology 2017 被引用: 589

  19. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

    著者: Hope S. Rugo, Fabrice André, Toshinari Yamashita, Humberto Cerda, I. Toledano, Salomon M. Stemmer, Josefina Cruz Jurado, Dejan Juric, Ingrid A. Mayer, Eva Ciruelos, Hiroji Iwata, PierFranco Conte, Mario Campone, C. Wilke, David Mills, Agnes Lteif, Michelle C. Miller, Fiorenza Gaudenzi, Sibylle Loibl - Annals of Oncology 2020 被引用: 187

  20. Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

    著者: Dejan Juric, Filip Jankú, Jordi Rodón, Howard A. Burris, Ingrid A. Mayer, Martin Schüler, Ruth Seggewiss‐Bernhardt, Marta Gil-Martín, Mark R. Middleton, José Baselga, Douglas Bootle, David Demanse, Lars Blumenstein, Karl Schumacher, Alan Huang, Cornelia Quadt, Hope S. Rugo - JAMA Oncology 2018 被引用: 260

  21. Resistance to Trastuzumab in Breast Cancer

    著者: Paula R. Pohlmann, Ingrid A. Mayer, Ray Mernaugh - Clinical Cancer Research 2009 被引用: 507

  22. Management of toxicity to isoform α-specific PI3K inhibitors

    著者: Sara Nunnery, Ingrid A. Mayer - Annals of Oncology 2019 被引用: 135

  23. NCCN Guidelines Insights: Breast Cancer, Version 1.2017

    著者: William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice A. Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth O’Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth Reed, Kilian Salerno, Lee S. Schwartzberg, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Dorothy A. Shead, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2017 被引用: 542

  24. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

    著者: Ángel Guerrero‐Zotano, Ingrid A. Mayer, Carlos L. Arteaga - Cancer and Metastasis Reviews 2016 被引用: 437